The rating reflects Partners’ exceptional enterprise profile, including its preeminent research program and tertiary and quaternary offerings, while also taking into account the abrupt resignation of CEO David Torchiana, MD.
The rating outlook is stable.
More articles on healthcare finance:
Moody’s affirms “MIG 2” for Yukon-Kuskokwim Health Corp
HCA more than doubles profit in Q4
Emergency physicians propose 6-point plan to end balance billing
